In cryptogenic stroke and atrial cardiopathy, apixaban did not reduce recurrent stroke vs. aspirin.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38830225.
- Also identified by DOI 10.7326/ANNALS-24-00436-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kamel H, Longstreth WT Jr, Tirschwell DL, et al; ARCADIA Investigators. <b>Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial.</b> JAMA. 2024;331:573-581. 38324415.
Medical subject headings
- Aspirin
- Atrial Fibrillation
- Factor Xa Inhibitors
- Pyrazoles
- Pyridones
- Recurrence
- Secondary Prevention